Lipocine Inc. LPCN
Set alert
At close
Pre-market · Nov 2, 4:02 AM ET
- YTD
- -82.07%
- 1 year
- -44.62%
- Open
- 1.50
- Prev close
- 1.52
- Mkt cap
- 11.87M
- Vol
- 112.05K
- Avg vol
- 1.80M
- EPS
- -1.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.42
- High
- 1.50
- Forward P/E
- -3.87
- Beta
- 1.19
- Short ratio
- 2.80
- Inst. own
- 9.96%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.16
- 200-d avg
- 5.39
- 1y target
- 21.50
News
3 weeks ago benzinga.com
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
3 weeks ago benzinga.com
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.
3 weeks ago benzinga.com
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday's pre-market session. Lipocine (NASDAQ:LPCN) shares rose 52.38% to $3.2. The company's market cap…
-
3 weeks ago benzinga.com
Lipocine Licensing Partner Verity Pharmaceuticals Receives Health Canada Approval For TLANDO Capsules For Testosterone Replacement Therapy In Adult Males
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine’s licensing partner Verity…